Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Editor’s Corner: Why an AZ-BMS merger would be a very bad idea
A merger risks severe regulatory concerns, pipeline disruptions and layoffs, while damaging the broader biopharma ecosystem, argues Fierce's Angus Liu
Angus Liu
Aug 3, 2026 12:25am
What Hub Transitions Really Cost Manufacturers
Brought to you by
Gifthealth
Amgen doesn't think Repatha's sales wins will stop anytime soon
Aug 4, 2026 4:01pm
Gilead prevails in yearslong HIV drug innovation case
Aug 4, 2026 3:00pm
Merck charts long-term path for first PCSK9 pill
Aug 4, 2026 2:38pm
More reductions for Pfizer as it tacks on $2.5B in cost savings
Aug 4, 2026 11:33am
More News
J&J innovative medicine chief Jennifer Taubert to retire
Aug 4, 2026 10:55am
Bayer CEO Anderson sticking out firm's revitalization scheme
Aug 4, 2026 10:40am
Fiercest Women in Life Sciences 2026: Nominations open now
Aug 4, 2026 10:00am
Jazz to withdraw Zepzelca in second-line small cell lung cancer
Aug 4, 2026 9:18am
